Publications
Detailed Information
Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Bohwa | - |
dc.contributor.author | Song, Yeonju | - |
dc.contributor.author | Park, Jeehun | - |
dc.contributor.author | Doh, Junsang | - |
dc.date.accessioned | 2024-05-16T01:21:08Z | - |
dc.date.available | 2024-05-16T01:21:08Z | - |
dc.date.created | 2022-04-20 | - |
dc.date.created | 2022-04-20 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.citation | Journal of Controlled Release, Vol.343, pp.379-391 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://hdl.handle.net/10371/202444 | - |
dc.description.abstract | © 2022Recent clinical successes of chimeric antigen receptor (CAR) T cell therapy have led the booming of developments in cancer immunotherapy utilizing ex vivo engineered immune cells such as T cells and natural killer (NK) cells. However, a number of issues need to be resolved for this novel therapy to become widely applicable to cancer patients as current CAR-T cell therapies are only successful in treating some blood cancers, and economically not feasible for many patients. In this review, we describe various nanomaterial-based approaches developed to overcome current limitations in ex vivo engineered T/NK cells, along with key biological principles underlying each approach. First, nanomaterials developed to improve ex vivo expansion of T/NK cells and the basic principles of T/NK cell activation for designing nanomaterials are summarized. Second, nanomaterial-based gene delivery methods to generate genetically engineered T/NK cells are discussed with an emphasis on challenges in improving transfection efficacy. Third, nanomaterials loaded to T/NK cells to enhance their anti-tumor functions and to overcome tumor microenvironment are described with key biological characteristics of T/NK cells, which are essential for nanomaterial loading and drug release from the nanomaterials. In particular, we comment on similarities and differences of methods developed for T cells and NK cells based on the biological characteristics of each cell type. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.01.049 | - |
dc.citation.journaltitle | Journal of Controlled Release | - |
dc.identifier.wosid | 000782077500003 | - |
dc.identifier.scopusid | 2-s2.0-85124202666 | - |
dc.citation.endpage | 391 | - |
dc.citation.startpage | 379 | - |
dc.citation.volume | 343 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Doh, Junsang | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | NATURAL-KILLER-CELLS | - |
dc.subject.keywordPlus | ANTIGEN-PRESENTING CELLS | - |
dc.subject.keywordPlus | GOLD NANOPARTICLES | - |
dc.subject.keywordPlus | MESSENGER-RNA | - |
dc.subject.keywordPlus | EXPANSION | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | IMMUNOMODULATORS | - |
dc.subject.keywordAuthor | Cancer immunotherapy | - |
dc.subject.keywordAuthor | Nanomaterials | - |
dc.subject.keywordAuthor | NK cells | - |
dc.subject.keywordAuthor | T cells | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.